Search Results - "Chambers, Emily S"
-
1
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd
Published in Cancer research (Chicago, Ill.) (01-01-2022)“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text
Journal Article -
2
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
Published in Clinical cancer research (01-12-2018)“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text
Journal Article -
3
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Published in Cancer immunology research (01-04-2016)“…The recent approval of two PD-1 inhibitors for the treatment of non-small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in…”
Get more information
Journal Article -
4
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer
Published in Clinical cancer research (15-05-2020)“…Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches…”
Get full text
Journal Article -
5
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations
Published in Molecular oncology (01-01-2021)“…Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation…”
Get full text
Journal Article -
6
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Published in Journal for immunotherapy of cancer (20-12-2016)“…BackgroundTumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with…”
Get full text
Journal Article -
7
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers
Published in Cancer cell (11-05-2020)“…While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments are lacking. Here, we report that half of KRAS-mutant NSCLCs…”
Get full text
Journal Article -
8
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer
Published in Molecular cancer therapeutics (01-04-2021)“…gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB…”
Get full text
Journal Article -
9
Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer
Published in Clinical cancer research (01-08-2020)“…We pursued genomic analysis of an exceptional responder with non-small cell lung cancer (NSCLC) through a multi-platform effort to discover novel oncogenic…”
Get full text
Journal Article -
10
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
Published in Science translational medicine (01-09-2021)“…The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in -mutant non–small cell lung cancer is limited by the development of drug…”
Get more information
Journal Article -
11
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer
Published in Nature cancer (18-04-2022)“…Despite advances in precision medicine, the clinical prospects for patients with ovarian and uterine cancers have not substantially improved. Here, we analyzed…”
Get full text
Journal Article -
12
Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers
Published in Journal of clinical oncology (20-05-2016)“…Abstract only…”
Get full text
Journal Article -
13
Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS- mutant NSCLC models
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Abstract Introduction: RAS mutations are present in 30% of non-small cell lung cancer (NSCLC) and, despite activated MAPK signaling, MEK inhibitors have…”
Get full text
Journal Article -
14
Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC)
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
15
Abstract 1028: Phosphate dysregulation as a novel therapeutic strategy in ovarian and uterine cancers
Published in Cancer research (Chicago, Ill.) (15-06-2022)“…Abstract Precision medicine promises to improve the treatment of cancer patients, but a lack of therapeutic targets and associated predictive biomarkers limit…”
Get full text
Journal Article